| 1 |
35033575 | Selinexor improves the anti-cancer effect of tucidinostat on TP53 wild-type breast cancer. | 2022 Apr 5 |
3 |
| 2 |
35217309 | Combining selinexor with alisertib to target the p53 pathway in neuroblastoma. | 2022 Apr |
4 |
| 3 |
33648535 | Selinexor versus doxorubicin in dedifferentiated liposarcoma PDXs: evidence of greater activity and apoptotic response dependent on p53 nuclear accumulation and survivin down-regulation. | 2021 Mar 1 |
1 |
| 4 |
34209894 | AML-Related NPM Mutations Drive p53 Delocalization into the Cytoplasm with Possible Impact on p53-Dependent Stress Response. | 2021 Jun 29 |
1 |
| 5 |
32045477 | Venetoclax response is enhanced by selective inhibitor of nuclear export compounds in hematologic malignancies. | 2020 Feb 11 |
1 |
| 6 |
33148342 | XPO1 expression worsens the prognosis of unfavorable DLBCL that can be effectively targeted by selinexor in the absence of mutant p53. | 2020 Nov 4 |
1 |
| 7 |
30037299 | Loss of p53 expression in cancer cells alters cell cycle response after inhibition of exportin-1 but does not prevent cell death. | 2018 |
2 |
| 8 |
30115935 | Anti-tumor efficacy of Selinexor (KPT-330) in gastric cancer is dependent on nuclear accumulation of p53 tumor suppressor. | 2018 Aug 16 |
3 |
| 9 |
27903750 | Nuclear Export of Ubiquitinated Proteins Determines the Sensitivity of Colorectal Cancer to Proteasome Inhibitor. | 2017 Apr |
5 |
| 10 |
26398108 | Pharmacodynamic and genomic markers associated with response to the XPO1/CRM1 inhibitor selinexor (KPT-330): A report from the pediatric preclinical testing program. | 2016 Feb |
1 |